ARCHIVES

NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

This article is from The Cancer Letter archive.

Vol. 40 No. 10 | March 7, 2014

Download PDF Visit The Full Archive

Related Articles

Clearinghouse Finds Five Compounds Pose Risk To Humans

March 2, 1979

NCI Adds New Wrinkle To Drug Distribution Plan – Individual Investigators To Work Through Centers

March 25, 1977

NIGMS Hosts Meeting On Increasing Minorities In Biomedical Careers

December 1, 1995

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

July 26, 2013

Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.

July 29, 2005

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005